TechnoVax, Inc. - Vaccines, Biologicals & Services

About Us

Technologies

Services

Media

Presentación en Español

Market Opportunities


	VLP Vaccine Technology
	Manufacturing
	Market Opportunities
	Competition
	Pipeline
	Intellectual Property

Annual vaccine sales worldwide are projected to reach about $18 billon and the vaccine market is projected to increase 12% per year.
Introduction of safe and efficacious novel vaccines manufactured with the most cost-effective technology will have significant commercial advantage and will potentially dominate the marketplace.

Potential Vaccine Targets Where VLP Technology Could Be Utilized

Primary Targets

Influenza A and B viruses
Vaccine available, dated technology,
Cumbersome manufacturing process

Respiratory Syncytial Virus (RSV).
No vaccine available

Parainfluenza virus (PIV)
No vaccine available

Metapneumovirus
No vaccine available

Secondary Targets

Hepatitis C virus
No vaccine available

West Nile Virus
No vaccine available

Coronavirus (SARS)
No vaccine available

Viral Hemorrhagic Fevers:
Dengue, Ebola, etc.
No vaccine available

Cancer Vaccine Targets
No vaccine available

Home	Contact Us